文献速递泌尿生殖与妇科肿瘤放疗

17基因基因组前列腺评分检测对临床局限性前列腺癌患者接受根治性外照射放疗后结局的预后价值

The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-10-25

该回顾性研究纳入2000至2016年在VA医疗系统接受外照射放疗的238例局限性前列腺癌患者(69%为黑人),评估Oncotype DX基因组前列腺评分(GPS)与生化失败、远处转移和前列腺癌特异性死亡的关系。GPS每增加20单位与三项终点均显著相关,多变量调整后仍显著,且黑人与非黑人之间无显著交互作用。

要点

  • GPS每增加20单位与生化失败(HR 3.62)、远处转移(HR 4.48)和前列腺癌特异性死亡(HR 5.36)显著相关。
  • 多变量调整基线临床和病理因素后GPS仍为独立预后指标,HR与单变量分析相似。
  • GPS与种族的交互作用无统计学意义(P=0.923),黑人与非黑人中生化失败HR相似。

核心结论

  • 在接受外照射放疗的局限性前列腺癌男性中,GPS检测是生化失败时间、远处转移和前列腺癌特异性死亡的强独立预后指标。
  • GPS检测在黑人和非黑人男性中表现相似。

研究设计与样本

  • 回顾性研究,纳入2000至2016年在北卡罗来纳州达勒姆VA医疗系统接受外照射放疗的局限性前列腺癌男性。
  • 共238例患者符合纳入标准,其中69%为黑人。
  • 研究终点为按Phoenix标准定义的生化失败时间、远处转移和前列腺癌特异性死亡。
  • 采用单变量和多变量Cox比例风险模型评估GPS结果(每20单位增加或二分类变量0-40 vs 41-100)与各终点的关联,并按种族分层分析。

主要发现

  • 未发生生化失败患者的中位随访时间为7.6年。
  • 单变量分析中,GPS每增加20单位与生化失败显著相关(HR 3.62;95%CI 2.59-5.02)。
  • 单变量分析中,GPS每增加20单位与远处转移显著相关(HR 4.48;95%CI 2.75-7.38)。
  • 单变量分析中,GPS每增加20单位与前列腺癌特异性死亡显著相关(HR 5.36;95%CI 3.06-9.76)。
  • 多变量模型中调整基线临床和病理因素后GPS仍显著,HR与单变量分析相似;GPS与种族交互作用无统计学意义(P=0.923);黑人男性生化失败HR 3.88(95%CI 2.40-6.24)vs 非黑人男性HR 4.01(95%CI 2.42-6.45)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The Oncotype DX Genomic Prostate Score (GPS) assay has been validated as a strong prognostic indicator of adverse pathology, biochemical recurrence, distant metastasis (DM), and prostate cancer (PCa)-related death (PCD) in men with localized PCa after radical prostatectomy. However, it has yet to be tested in men undergoing external beam radiation therapy (EBRT), for whom assessing PCa progression risk could inform decisions on treatment intensity. We analyzed whether GPS results are associated with time to biochemical failure (BCF), DM, and PCD after EBRT in men with localized PCa and whether the association is modified by race. METHODS AND MATERIALS: We conducted a retrospective study of men with localized PCa treated with EBRT at the VA Health Care System in Durham, NC from 2000 to 2016. Study endpoints were time to BCF per the Phoenix criteria, DM, and PCD. The association of GPS results, per 20-unit increase or dichotomous variable (0-40 vs 41-100), was evaluated with each endpoint using univariable and multivariable Cox proportional hazards models. Results were then stratified by race. RESULTS: A total of 238 patients (69% Black) met the eligibility criteria. Median follow-up for patients who did not experience BCF was 7.6 years. GPS results per 20-unit increase were significantly associated with BCF (hazard ratio [HR], 3.62; 95% confidence interval [CI], 2.59-5.02), DM (HR, 4.48; 95% CI, 2.75-7.38), and PCD (HR, 5.36; 95% CI, 3.06-9.76) in univariable analysis. GPS results remained significant in multivariable models adjusted for baseline clinical and pathological factors, with HRs being similar to the univariable analysis. There was no significant interaction between the GPS assay and race (P = .923). HRs for BCF were similar in Black men (HR, 3.88; 95% CI, 2.40-6.24) versus non-Black men (HR, 4.01; 95% CI, 2.42-6.45). CONCLUSIONS: Among men treated with EBRT, the GPS assay is a strong, independent prognostic indicator of time to BCF, DM, and PCD, and performs similarly in Black and non-Black men.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Janes JL, Boyer MJ, Bennett JP, et al. The 17-Gene Genomic Prostate Score Test Is Prognostic for Outcomes After Primary External Beam Radiation Therapy in Men With Clinically Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022. PMID: 36306979. doi:10.1016/j.ijrobp.2022.06.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。